biote Corp. (BTMD) presents a deeply negative liquidation posture as of March 31, 2026. MFFAIS computed liquidation values are: cash liquidation value -$119.0M, liquid liquidation value -$112.1M, and operating liquidation value -$93.0M. These figures reflect the structural asymmetry typical of a franchise/service-model going concern: the asset base is dominated by intangibles and goodwill (franchise value, practitioner network, proprietary software, Biote Method training IP) that carry zero liquidation recovery, while the liability stack — including a senior secured term loan — remains at face value. The TAG_CONTEXT provided contains no XBRL tags with values, preventing tag-level quantification from the XBRL data set directly. All dollar figures below are sourced from the narrative and financial tables in the filing body. Cash as of March 31, 2026 was $5.3M, down sharply from $24.1M at December 31, 2025. The $18.8M decline is primarily attributable to the $18.5M cash payment in January 2026 to fully settle the Donovitz share repurchase liability, plus $1.1M in open-market share repurchases under the Board's buyback program, partially offset by $3.9M in operating cash flow. The financing cash outflow of $21.5M in Q1 2026 versus $2.3M in Q1 2025 is the dominant driver of the cash depletion. On the liability side, a material post-period event occurred on May 8, 2026: the Company entered into an amended and restated credit agreement with Truist Bank totaling $175.0M, comprising a $125.0M term loan (drawn in full at closing) and a $50.0M revolving facility. This replaces the prior Truist credit agreement dated May 22, 2022. As of March 31, 2026, the prior term loan was still in place with $5.0M drawn on the revolver; the refinancing closes after the balance sheet date and is not reflected in the March 31, 2026 balance sheet. The new $125M term loan, when recorded in Q2 2026, will materially increase the long-term debt balance and worsen the liquidation deficit — that increment is discussed in MD&A and a subsequent event footnote but is not yet on the reported balance sheet. Inventory quality is impaired: the January 2026 Voluntary Recall of specific Asteria Health hormone pellet lots resulted in a $1.3M inventory impairment charge taken in Q4 2025. The recall also forced a sourcing shift to higher-cost third-party outsourcing facilities, compressing gross margin (cost of pellet procedures up 7.7% while pellet procedure revenue fell 13.2% YoY in Q1 2026). Recall-related costs of $1.5M were expensed in Q1 2026, with additional costs expected. A new 127-month operating lease in Tampa, Florida (~40,000 sq ft) was signed April 24, 2026 as a subsequent event; the Company expects to record an ASC 842 right-of-use asset of approximately $4.6M and a corresponding lease liability when it gains access to premises — adding to the operating lease liability stack in a future period. An inventory purchase commitment of $6.3M extended through December 31, 2027 (extended April 9, 2026) represents an additional off-balance-sheet production obligation at face value in a wind-down scenario. The Company carries a long-standing unremediated material weakness in internal controls over financial reporting originating from fiscal years 2019-2020, which has not been remediated as of March 31, 2026. Revenue declined 8.3% YoY to $44.9M in Q1 2026, and Adjusted EBITDA fell to $8.7M from $13.8M in Q1 2025, reflecting the recall impact plus elevated legal and SG&A expenses. Net income was $2.7M versus $15.8M in Q1 2025, though the prior period included a $10.7M non-cash gain from earnout liability fair value changes versus $2.1M in the current period. The filing does not separately XBRL-tag balance sheet line items, long-term debt balances, goodwill, intangible assets, inventory, accounts receivable, operating lease liabilities, earnout liabilities, or the revolving/term loan balances in the TAG_CONTEXT provided — all are absent from XBRL tagging and can only be referenced from the narrative.
▼ Community Notes